Hope for Allergy Sufferers as Altamira Publishes Positive Results from Rhinitis Study

Results from Altamira Therapeutics’ (Nasdaq:CYTO) NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) has been accepted for publication in Allergy, one of the highest-ranking journals in the field of allergology. Bentrio is an OTC nasal spray for allergic rhinitis and a commercial-stage legacy asset for Altamira.

Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites. Altamira tested Bentrio versus saline nasal spray in 100 patients during two allergy seasons in Australia. The study met its primary efficacy endpoint of improvement in nasal symptoms and demonstrated statistically significant improvement in health-related quality of life and reduced need for relief medication.

“We are thrilled to see the detailed results from our pivotal Australian trial published in one the leading medical journals in allergology,” commented Thomas Meyer, Altamira’s founder, Chairman, and CEO. “We are very encouraged to see that Bentrio helps to manage not only mild allergy symptoms, but also more severe ones, and appears to reduce the need for the use of drug-based relief treatments.”

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/

Share This Article

 

About the Author

Hope for Allergy Sufferers as Altamira Publishes Positive Results from Rhinitis Study

Catie Corcoran

Biotech Editor